Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Diarrhea
Gastrointestinal Complications

Interventions: Biological: filgrastim
Drug: cyclophosphamide

First Posted Date: 2005-11-24

Last Posted Date: 2019-04-16

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 3

Registration Number: NCT00258180

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: rituximab
Drug: cyclophosphamide

First Posted Date: 2005-11-24

Last Posted Date: 2017-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 21

Registration Number: NCT00258206

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Phase 2

Completed

Conditions: Fanconi Anemia

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methylprednisolone
Biological: Hematopoietic stem cell transplantation

First Posted Date: 2005-11-24

Last Posted Date: 2021-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 14

Registration Number: NCT00258427

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Carboplatin
Drug: GM-CSF
Drug: Trastuzumab

First Posted Date: 2005-11-21

Last Posted Date: 2018-03-02

Lead Sponsor: Rita Sanghvi, Mehta

Target Recruit Count: 48

Registration Number: NCT00256243

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: graft-versus-tumor induction therapy
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2005-11-21

Last Posted Date: 2016-11-03

Lead Sponsor: University of Rochester

Target Recruit Count: 16

Registration Number: NCT00255684

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2005-11-21

Last Posted Date: 2010-03-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 60

Registration Number: NCT00255710

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Neoadjuvant Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: GM-CSF
Drug: Trastuzumab
Drug: Bevacizumab

First Posted Date: 2005-11-16

Last Posted Date: 2019-02-28

Lead Sponsor: University of California, Irvine

Target Recruit Count: 43

Registration Number: NCT00254592

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mitoxantrone
Drug: Rituximab
Drug: Filgrastim

First Posted Date: 2005-11-16

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00254410

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

Phase 3

Completed

Conditions: B-Cell Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Pentostatin

First Posted Date: 2005-11-15

Last Posted Date: 2016-11-03

Lead Sponsor: US Oncology Research

Target Recruit Count: 184

Registration Number: NCT00254163

Locations: 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸
St Joseph Oncology, Inc, St Joseph, Missouri, United States
🇺🇸
Alliance Hematology Oncology PA, Westminster, Maryland, United States

and more 8 locations

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Not Applicable

Terminated

Conditions: Myelodysplastic/Myeloproliferative Diseases
Lymphoma
Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Sarcoma
Chronic Myeloproliferative Disorders
Graft Versus Host Disease

First Posted Date: 2005-11-15

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 4

Registration Number: NCT00253552

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy